Business Context and Reporting Period
This Form 8-K is a current report filed by Aquestive Therapeutics, Inc. on July 2, 2020. The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol AQST. The filing identifies the registrant as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure vehicle for a qualitative event rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the body of this specific filing. The report focuses solely on the disclosure of a recent communication.
Guidance, Outlook, and Management Commentary
Item 7.01 discloses that the Company's President and CEO, Keith Kendell, participated in a Q&A session published by The Fly on July 2, 2020. The full text of this Q&A is attached as Exhibit 99.1. The filing explicitly states that this information is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (the Q&A with The Fly) for specific management commentary, as the 8-K body only references its existence.
- Verify the company's status as an emerging growth company and any associated reporting exemptions.
- Confirm that the Q&A content does not contain forward-looking statements that have been superseded by subsequent filings.
- Note that the Q&A is not legally "filed" under Section 18 of the Exchange Act, which may affect liability standards for the information contained therein.